Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer

被引:6
|
作者
Ferreira, M. R. [1 ,2 ,4 ,5 ]
Thomas, K. [2 ]
Truelove, L. [1 ,2 ]
Khan, A. [1 ,2 ]
Parker, C. [1 ,2 ]
Dearnaley, D. P. [1 ,2 ]
Gulliford, S. [1 ,3 ]
机构
[1] Inst Canc Res, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Kings Coll London, London, England
关键词
Dose-volume constraints; dosimetry; IMRT; pelvic lymph nodes; prostate cancer; gastrointestinal side-effects; SMALL-BOWEL TOXICITY; RADIATION-THERAPY; RECTAL TOXICITY; NORMAL TISSUE; VOLUME; 3D-CRT; PREDICTORS; IMRT;
D O I
10.1016/j.clon.2019.02.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Pelvic lymph node (PLN) radiotherapy for high-risk prostate cancer is limited by late gastrointestinal toxicity. Application of rectal and bowel constraints may reduce risks of side-effects. We evaluated associations between intensity-modulated radiotherapy (IMRT) dose-volume data and long-term gastrointestinal toxicity. Materials and methods: Data from a single-centre dose-escalation trial of PLN-IMRT were analysed, including conventionally fractionated (CFRT) and hypofractionated (HFRT) radiotherapy schedules. Associations between volumes of rectum and bowel receiving specified doses and clinician- and patient-reported toxicity outcomes were investigated independently. A metric, delta median (delta M), was defined as the difference in the medians of a volume between groups with and without toxicity at a specified dose and was used to test for statistically significant differences. Results: Constraints were respected in most patients and, when exceeded, led to higher rates of gastrointestinal toxicity. Biologically relevant associations between rectum dose-points and toxicity were more numerous with both mild and moderate toxicity thresholds, but statistical significance was limited after correction for false discovery rate. Rectal V50Gy (CFRT) associated with grade 2+ bleeding; bowel V43Gy and V47 (HFRT/4 days/week schedule) associated with patient-reported loose stools and diarrhoea, respectively. Further investigation showed that CFRT patients with rectal bleeding had a mean rectal V50Gy above the treatment planning constraint. Conclusions: When dose-volume parameters are kept below tight constraints, toxicity is low. Residual dosimetry loses much of its predictive power for gastrointestinal toxicity in the setting of PLN-IMRT for prostate cancer. We have benchmarked dose-volume constraints for safely delivering PLN-IMRT using CFRT or HFRT. (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd.
引用
收藏
页码:374 / 384
页数:11
相关论文
共 50 条
  • [1] Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
    Dearnaley, David
    Griffin, Clare L.
    Lewis, Rebecca
    Mayles, Philip
    Mayles, Helen
    Naismith, Olivia F.
    Harris, Victoria
    Scrase, Christopher D.
    Staffurth, John
    Syndikus, Isabel
    Zarkar, Anjali
    Ford, Daniel R.
    Rimmer, Yvonne L.
    Horan, Gail
    Khoo, Vincent
    Frew, John
    Venkitaraman, Ramachandran
    Hall, Emma
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (03): : 605 - 617
  • [2] Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer
    Tsuchida, Keisuke
    Inaba, Koji
    Kashihara, Tairo
    Murakami, Naoya
    Okuma, Kae
    Takahashi, Kana
    Igaki, Hiroshi
    Nakayama, Yuko
    Maejima, Aiko
    Shinoda, Yasuo
    Matsui, Yoshiyuki
    Komiyama, Motokiyo
    Fujimoto, Hiroyuki
    Ito, Yoshinori
    Sumi, Minako
    Nakano, Takashi
    Itami, Jun
    CANCER MEDICINE, 2020, 9 (18): : 6629 - 6637
  • [3] When is Elective Pelvic Lymph Node Irradiation Indicated in Definitive Radiotherapy for Localized Prostate Cancer?
    Mendenhall, William M.
    Hoppe, Bradford S.
    Nichols, R. Charles
    Henderson, Randal H.
    Mendenhall, Nancy P.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (06): : 644 - 647
  • [4] Pelvic lymph node recurrence in high-risk prostate cancer following prostate-only radiotherapy
    Hussain, Sameed
    Wajid, Muhammad Imran
    Omer, Muhammad
    Khan, Muhammad Yousuf
    Maqsood, Talha
    Zeb, Adnan
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2021, 22
  • [5] Outcomes of Sterotactic Body Radiotherapy (SBRT) for pelvic lymph node recurrences after adjuvant or primary radiotherapy for prostate cancer
    Gamsiz, Hakan
    Sager, Omer
    Uysal, Bora
    Dincoglan, Ferrat
    Demiral, Selcuk
    Ozcan, Fatih
    Colak, Onurhan
    Dirican, Bahar
    Beyzadeoglu, Murat
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 : S851 - S856
  • [6] Outcomes of Sterotactic Body Radiotherapy (SBRT) for pelvic lymph node recurrences after adjuvant or primary radiotherapy for prostate cancer
    Gamsiz, Hakan
    Sager, Omer
    Uysal, Bora
    Dincoglan, Ferrat
    Demiral, Selcuk
    Ozcan, Fatih
    Colak, Onurhan
    Dirican, Bahar
    Beyzadeoglu, Murat
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 2) : S851 - S856
  • [7] Treatment of prostate cancer using external beam radiotherapy after laparoscopic pelvic lymph node dissection
    Gerber, GS
    Bales, GT
    Gornik, HL
    Haraf, DJ
    Chodak, GW
    Rukstalis, DB
    BRITISH JOURNAL OF UROLOGY, 1996, 77 (06): : 870 - 875
  • [8] Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
    McDonald, Andrew M.
    Baker, Christopher B.
    Popple, Richard A.
    Shekar, Kiran
    Yang, Eddy S.
    Jacob, Rojymon
    Cardan, Rex
    Kim, Robert Y.
    Fiveash, John B.
    RADIATION ONCOLOGY, 2014, 9
  • [9] OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer
    Supiot, Stephane
    Rio, Emmanuel
    Pacteau, Valerie
    Mauboussin, Marie-Helene
    Campion, Loic
    Pein, Francois
    BMC CANCER, 2015, 15
  • [10] Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial
    Kim, Julian O.
    McDonald, Megan O.
    Ong, Aldrich
    Koul, Rashmi
    Dubey, Arbind
    Hunter, William
    Ahmed, Shahida
    Quon, Harvey
    Yee, Don
    Parliament, Matthew
    Sivananthan, Gokulan
    Danielson, Brita
    Rowe, Lindsay
    Ghosh, Sunita
    Usmani, Nawaid
    RADIATION ONCOLOGY, 2021, 16 (01)